TTK HEALTHCARE | IPCA LABS | TTK HEALTHCARE/ IPCA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 11.8 | 21.7 | 54.5% | View Chart |
P/BV | x | 1.7 | 7.8 | 22.1% | View Chart |
Dividend Yield | % | 0.9 | 0.2 | 576.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TTK HEALTHCARE Mar-19 |
IPCA LABS Mar-19 |
TTK HEALTHCARE/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,215 | 1,042 | 116.6% | |
Low | Rs | 610 | 590 | 103.4% | |
Sales per share (Unadj.) | Rs | 444.4 | 298.6 | 148.8% | |
Earnings per share (Unadj.) | Rs | 17.2 | 35.0 | 49.3% | |
Cash flow per share (Unadj.) | Rs | 27.6 | 49.4 | 55.9% | |
Dividends per share (Unadj.) | Rs | 5.00 | 3.00 | 166.7% | |
Dividend yield (eoy) | % | 0.5 | 0.4 | 149.0% | |
Book value per share (Unadj.) | Rs | 177.9 | 247.1 | 72.0% | |
Shares outstanding (eoy) | m | 14.13 | 126.35 | 11.2% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 2.1 | 2.7 | 75.2% | |
Avg P/E ratio | x | 52.9 | 23.3 | 226.9% | |
P/CF ratio (eoy) | x | 33.0 | 16.5 | 200.1% | |
Price / Book Value ratio | x | 5.1 | 3.3 | 155.3% | |
Dividend payout | % | 29.0 | 8.6 | 338.2% | |
Avg Mkt Cap | Rs m | 12,894 | 103,108 | 12.5% | |
No. of employees | `000 | 2.3 | 13.4 | 17.2% | |
Total wages/salary | Rs m | 1,307 | 7,874 | 16.6% | |
Avg. sales/employee | Rs Th | 2,715.7 | 2,807.0 | 96.7% | |
Avg. wages/employee | Rs Th | 565.3 | 585.8 | 96.5% | |
Avg. net profit/employee | Rs Th | 105.4 | 329.0 | 32.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,279 | 37,732 | 16.6% | |
Other income | Rs m | 78 | 577 | 13.4% | |
Total revenues | Rs m | 6,356 | 38,309 | 16.6% | |
Gross profit | Rs m | 496 | 6,901 | 7.2% | |
Depreciation | Rs m | 147 | 1,824 | 8.0% | |
Interest | Rs m | 34 | 189 | 17.9% | |
Profit before tax | Rs m | 393 | 5,465 | 7.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 149 | 1,042 | 14.3% | |
Profit after tax | Rs m | 244 | 4,422 | 5.5% | |
Gross profit margin | % | 7.9 | 18.3 | 43.2% | |
Effective tax rate | % | 37.9 | 19.1 | 198.8% | |
Net profit margin | % | 3.9 | 11.7 | 33.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,717 | 23,778 | 11.4% | |
Current liabilities | Rs m | 1,571 | 10,975 | 14.3% | |
Net working cap to sales | % | 18.3 | 33.9 | 53.8% | |
Current ratio | x | 1.7 | 2.2 | 79.8% | |
Inventory Days | Days | 32 | 104 | 31.0% | |
Debtors Days | Days | 47 | 66 | 70.8% | |
Net fixed assets | Rs m | 991 | 20,368 | 4.9% | |
Share capital | Rs m | 141 | 253 | 55.9% | |
"Free" reserves | Rs m | 2,373 | 30,971 | 7.7% | |
Net worth | Rs m | 2,514 | 31,224 | 8.1% | |
Long term debt | Rs m | 3 | 1,409 | 0.2% | |
Total assets | Rs m | 4,158 | 45,507 | 9.1% | |
Interest coverage | x | 12.6 | 30.0 | 42.1% | |
Debt to equity ratio | x | 0 | 0 | 3.0% | |
Sales to assets ratio | x | 1.5 | 0.8 | 182.1% | |
Return on assets | % | 6.7 | 10.1 | 65.9% | |
Return on equity | % | 9.7 | 14.2 | 68.4% | |
Return on capital | % | 16.9 | 17.3 | 97.8% | |
Exports to sales | % | 3.6 | 45.9 | 7.8% | |
Imports to sales | % | 0.5 | 16.6 | 3.0% | |
Exports (fob) | Rs m | 225 | 17,308 | 1.3% | |
Imports (cif) | Rs m | 31 | 6,266 | 0.5% | |
Fx inflow | Rs m | 225 | 17,308 | 1.3% | |
Fx outflow | Rs m | 71 | 6,266 | 1.1% | |
Net fx | Rs m | 154 | 11,042 | 1.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 173 | 4,923 | 3.5% | |
From Investments | Rs m | 97 | -1,563 | -6.2% | |
From Financial Activity | Rs m | -307 | -1,832 | 16.8% | |
Net Cashflow | Rs m | -38 | 1,528 | -2.5% |
Indian Promoters | % | 65.4 | 45.9 | 142.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 11.4 | 32.5% | |
FIIs | % | 5.2 | 25.3 | 20.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 25.8 | 17.4 | 148.3% | |
Shareholders | 12,723 | 36,892 | 34.5% | ||
Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare TTK HEALTHCARE With: UNICHEM LAB VENUS REMEDIES CIPLA WOCKHARDT AUROBINDO PHARMA
Compare TTK HEALTHCARE With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended December 2020, TTK HEALTHCARE has posted a net profit of Rs 77 m (up 71.7% YoY). Sales on the other hand came in at Rs 2 bn (up 8.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended December 2019, TTK HEALTHCARE has posted a net profit of Rs 45 m (down 8.3% YoY). Sales on the other hand came in at Rs 2 bn (up 11.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this video, I'll show you how to allocate your capital as a day trader.
More